Table 3 Association between intake of at least one systemic antiherpetic drugs and incidence of dementia - Cox models. ‶Echantillon Généraliste des Bénéficiaires.″ 2009–2017
From: Antiherpetic drugs: a potential way to prevent Alzheimer’s disease?
Adjusted modela | ||||
|---|---|---|---|---|
Events | aHR | 95% CI | P-value | |
In all the subjects (n= 68291) | ||||
All dementias | 8883 | 0.90 | 0.82–0.99 | 0.03 |
Alzheimer’s disease | 5366 | 0.85 | 0.75–0.96 | 0.009 |
Vascular dementia | 1784 | 0.80 | 0.65–0.995 | 0.045 |
After exclusion of immunocompromised subjects, subjects with cancer or with an hospitalization related to herpesviruses (n=52254) | ||||
All dementias | 7044 | 0.84 | 0.75–0.94 | 0.002 |
Alzheimer’s disease | 4260 | 0.82 | 0.71–0.95 | 0.007 |
Vascular dementia | 1433 | 0.77 | 0.60–0.99 | 0.04 |
After carrying out a lag-time of 1 year (n= 68291) | ||||
All dementias | 8883 | 0.86 | 0.78–0.95 | 0.004 |
Alzheimer’s disease | 5366 | 0.78 | 0.68–0.90 | 0.001 |
Vascular dementia | 1784 | 0.87 | 0.69–1.09 | 0.23 |
After exclusion of participants with ≥ 2 deliveries of systemic AHDs per year of follow-up (n= 67904) | ||||
All dementias | 8856 | 0.91 | 0.83–0.997 | 0.04 |
Alzheimer’s disease | 5351 | 0.85 | 0.75–0.97 | 0.01 |
Vascular dementia | 1781 | 0.83 | 0.66–1.03 | 0.09 |